Evidence map›Paper›PMID 24030016›Full record

ArticleCirculation research2013

Why has it taken so long to learn what we still don't know?

Mark E Anderson

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Mark E AndersonFrom the University of Iowa Department of Internal Medicine, Division of Cardiovascular Medicine, Cardiovascular Research Center and the Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA.

Funding

Mitochondrial Calmodulin Kinase II in Physiology and DiseaseR01HL070250 · NHLBI · VANDERBILT UNIVERSITY · PI ANDERSON, MARK E · 2002 to 2017
$5.2M
Thoracic Veins and Sustained Atrial FibrillationR01HL071140 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI CHEN, PENG-SHENG · 2002 to 2014
$4.7M
Methionine sulfoxide reductase A and oxidized CaMKII in structural heart diseaseR01HL079031 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2006 to 2015
$3.3M
CaMKII in Sinus Node Physiology and DiseaseR01HL096652 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2009 to 2016
$3.0M
Oxidized CaMKII in Atrial FibrillationR01HL113001 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2012 to 2016
$1.9M
NHLBI NIH HHS R01 HL070250NHLBI NIH HHS R01-HL070250NHLBI NIH HHS R01 HL071140NHLBI NIH HHS R01-HL071140NHLBI NIH HHS R01 HL079031NHLBI NIH HHS R01-HL 079031NHLBI NIH HHS R01 HL096652NHLBI NIH HHS R01-HL096652NHLBI NIH HHS R01 HL113001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adrenergic AgentsAnimalsCalcium Channels, L-TypeMyocytes, CardiacAdrenergic AgentsCalcium Channels, L-TypeL-type calcium channel alpha(1C)CaV1.2Editorialsphosphorylationprotein kinases

Identifiers

PMID24030016
PMCPMC3871173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.